Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis


Published in:
BMJ Open Respiratory Research

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2014 The Authors
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis

David Hannon,1 Judy M Bradley,2 Ian Bradbury,2 Nicholas Bell,3 J Stuart Elborn,1 Katherine O’Neill1

ABSTRACT

Background: Lung clearance index (LCI) derived from sulfur hexafluoride (SF6) multiple breath washout (MBW) is a sensitive measure of lung disease in people with cystic fibrosis (CF). However, it can be time-consuming, limiting its use clinically.

Aim: To compare the repeatability, sensitivity and test duration of LCI derived from washout to 1/30th (LCI1/30), 1/20th (LCI1/20) and 1/10th (LCI1/10) to ‘standard’ LCI derived from washout to 1/40th initial concentration (LCI1/40).

Methods: Triplicate MBW test results from 30 clinically stable people with CF and 30 healthy controls were analysed retrospectively. MBW tests were performed using 0.2% SF6 and a modified Innocor device. All LCI end points were calculated using SimpleWashout software. Repeatability was assessed using coefficient of variation (CV%). The proportion of people with CF with and without abnormal LCI and forced expiratory volume in 1 s (FEV1) % predicted was compared. Receiver operating characteristic (ROC) curve statistics were calculated. Test duration of all LCI end points was compared using paired t tests.

Results: In people with CF, LCI1/40 CV% (p=0.16), LCI1/30 CV% (p=0.53), LCI1/20 CV% (p=0.14) and LCI1/10 CV % (p=0.25) was not significantly different to controls. The sensitivity of LCI1/40, LCI1/20 and LCI1/10 to the presence of CF was equal (67%). The sensitivity of LCI1/10 and FEV1 % predicted was lower (53% and 47% respectively). Area under the ROC (95% CI) for LCI1/40, LCI1/20 and LCI1/10 was 0.89 (0.80 to 0.97), 0.87 (0.77 to 0.96), 0.87 (0.78 to 0.96), 0.83 (0.72 to 0.94) and 0.73 (0.60 to 0.86), respectively. Test duration of LCI1/30, LCI1/20 and LCI1/10 was significantly shorter compared with the test duration of LCI1/40 in people with CF (p<0.0001) equating to a 5%, 9% and 15% time saving, respectively.

Conclusions: In this study, LCI1/20 was a repeatable and sensitive measure with equal diagnostic performance to LCI1/40. LCI1/20 was shorter, potentially offering a more feasible research and clinical measure.

KEY MESSAGES

- Lung Clearance Index (LCI) can be time-consuming, limiting its use clinically.
- Investigation of the flexibility of current multiple breath washout test end points is an important area for future research.
- LCI1/20 is a repeatable and sensitive test that is shorter than LCI1/40, potentially offering a more feasible research and clinical measure.

INTRODUCTION

Lung Clearance Index (LCI) derived from multiple breath washout (MBW) is a sensitive measure of ventilation inhomogeneity and a robust surrogate outcome measure of the severity of lung disease in cystic fibrosis (CF) which has begun to be incorporated into clinical trials. It also shows promise as a sensitive outcome measure in idiopathic bronchiectasis and asthma. A drawback of the test is that it can be time-consuming, especially in patients with advanced disease, limiting its feasibility within the clinical environment. By convention a MBW test involves performing a minimum of three inert tracer gas washout runs, ending the washout when end-tidal tracer gas concentration falls below 1/40th of the initial concentration. The end point of 1/40th is based on historic studies and has not been systematically validated. The European Respiratory Society/American Thoracic Society (ERS/ATS) consensus statement highlights investigation of the flexibility of current MBW test end points as an important area for future research, which could potentially improve the utility of this test. Assessment of the clinimetric properties of shortened LCI in CF using nitrogen (N2) MBW testing (100% as the inert gas), have reported good diagnostic performance in children with mild disease, offering a measure of ventilation inhomogeneity which may be more practical in the clinical setting. However, there are no studies to assess the performance of shortened LCI using sulfur hexafluoride (SF6) MBW...
(another common MBW method), or studies of shortened LCI in adult patients with more moderate to advanced disease. Differences in gas diffusion and molecular mass of the inert gases used mean that results of the two types of test are not comparable. Study of the sensitivity of shortened MBW tests using SF₆ could be useful in improving the clinical utility of these tests.

In this study we aimed to assess and compare the repeatability, sensitivity, specificity and test duration of LCI derived from washout to 1/30th (LCI₁/3₀, 1/20th (LCI₁/2₀) and 1/10th of the initial concentration (LCI₁/₁₀) to ‘standard’ LCI derived from washout to 1/40th initial concentration (LCI₁/₄₀), using 0.2% SF₆ as the tracer gas, in school age—adolescent children and adults with CF and healthy controls.

METHODS
Subject recruitment
Cross sectional data from 30 people with CF (n=15 aged 6–17 years old; n=15 aged ≥18 years old) and 30 healthy control participants (n=15 aged 6–17 years old; n=15 aged ≥18 years old) with three valid and repeatable MBW tests were analysed. Thirty anonymised CF and 30 healthy control data sets, as consecutively listed in a database of results collected in a large prospective project investigating the clinimetric and clinical relevance of LCI in CF were used. People with CF were recruited at a routine outpatient visit to the Northern Ireland paediatric and adult CF centres at Belfast Health and Social Care Trust (BHSCT), when clinically stable (no pulmonary exacerbation requiring intravenous antibiotics in the previous 4 weeks), between October 2010 and June 2013. Control participants were recruited by means of email circulation among people employed in Queen’s University Belfast (QUB) and BHSCT between September 2011 and August 2012. All adult participants provided written informed consent. All child participants provided child or young person assent and parental consent.

MBW testing
The MBW test to measure LCI was carried out using a modified Innocor device and 0.2% SF₆ using the open-circuit technique in accordance with the standard operating procedure developed by the UK CF Gene Therapy Consortium (UKCFGTC; see online supplementary file 1) as described and validated by Horsley et al and used in a recent CF clinical trial and observational study. Participants breathed through a mouthpiece at tidal volumes, while in a seated position and wearing a nose clip. Participants breathed 0.2% SF₆ in air via a flowpast circuit until washin was complete, at which point the flowpast was disconnected and the participant breathed room air until the end tidal expired SF₆ concentration fell below 1/40th of the initial concentration before disconnection. Three washouts were performed for each participant. Analysis of MBW data was performed using the SimpleWashout programme developed by Dr Nicholas Bell (UKCFGTC) and used with his permission (see online supplementary file 1). For each washout, four values for functional residual capacity (FRC) and LCI were calculated:

- FRC₁/₄₀ and LCI₁/₄₀ were derived from washout data from flowpast disconnection until the first breath with end tidal SF₆ concentration below 1/40th (≤0.005%) of the starting SF₆ concentration (0.2%).
- FRC₁/₃₀ and LCI₁/₃₀ were derived from washout data from flowpast disconnection until the first breath with end tidal SF₆ concentration below 1/30th (≤0.007%) of the starting SF₆ concentration (0.2%).
- FRC₁/₂₀ and LCI₁/₂₀ were derived from washout data from flowpast disconnection until the first breath with end tidal SF₆ concentration below 1/20th (≤0.01%) of the starting SF₆ concentration (0.2%).
- FRC₁/₁₀ and LCI₁/₁₀ were derived from washout data from flowpast disconnection until the first breath with end tidal SF₆ concentration below 1/10th (≤0.02%) of the starting SF₆ concentration (0.2%).

Mean LCI and FRC values and test duration (minutes) for each end point were calculated from each of the three washouts in each testing session.

Spirometry
Spirometry was measured according to American Thoracic Society/European Respiratory Society ATS/ERS guidelines using a Microlab (ML3500 MK8) spirometer (CareFusion, Kent, UK). Predicted values were calculated from reference ranges for all ages.

Statistical analysis
Data were analysed using PASW Statistics (V.18, IBM software, USA) and Prism (V.5.01 GraphPad Software Inc.) packages. CF and control participant characteristics were summarised using descriptive statistics.

Intravisit repeatability of LCI₁/₄₀, LCI₁/₃₀ LCI₁/₂₀ and LCI₁/₁₀ was assessed using the coefficient of variation (CV%) of all three tests and Bland-Altman plots comparing tests one and three, for people with CF and healthy controls. Results between people with CF and healthy controls were compared using an independent samples t test. Mean LCI and FRC values for each end point from people with CF or healthy controls were compared using paired samples t tests. The relationship between mean LCI₁/₄₀ and mean LCI₁/₃₀, LCI₁/₂₀ and LCI₁/₁₀ was assessed using scatter plots and the Spearman’s rank correlation coefficient. This analysis was also used to assess the relationship between FEV₁% predicted and all LCI end points. Sensitivity of all LCI end points compared with FEV₁% predicted was assessed using scatter plots and limits of normal of respective tests calculated from healthy controls (mean ±1.96 SD). Sensitivity and specificity were further analysed using receiver operating characteristic (ROC) curves, and by comparing area under the ROC curve (AUCROC) and 95% CI for LCI₁/₄₀, LCI₁/₃₀, LCI₁/₂₀, LCI₁/₁₀.
LCI$_{1/10}$ and FEV$_1$% predicted. Mean test duration (minutes) of LCI$_{1/40}$, LCI$_{1/30}$, LCI$_{1/20}$ and LCI$_{1/10}$ was compared using a paired samples t test. As multiple comparisons were being made, a Bonferroni adjustment was incorporated. A p value of <0.01 was considered statistically significant.

RESULTS

LCI$_{1/40}$, LCI$_{1/30}$, LCI$_{1/20}$ and LCI$_{1/10}$ and FEV$_1$% predicted were significantly different between the CF and control group. However, there was no difference between the CF and control group in age, sex, LCI$_{1/40}$ CV%, LCI$_{1/30}$ CV%, LCI$_{1/20}$ CV% and LCI$_{1/10}$ CV% or test duration of any LCI end point (table 1). There was no difference between the CF and control group in any of the FRC values (FRC$_{1/40}$, FRC$_{1/30}$, FRC$_{1/20}$ or FRC$_{1/10}$). Within the CF group, as expected, FRC was incrementally lower with each earlier end point. Although FRC$_{1/40}$ and FRC$_{1/30}$ were not significantly different (1.95 vs 1.93, p=0.07), FRC$_{1/20}$ (1.95 vs 1.90, p=0.002) and FRC$_{1/40}$ and FRC$_{1/10}$ (1.95 vs 1.84) were significantly different. However, there was no difference between the CF and control group in age, sex, LCI$_{1/40}$ CV%, LCI$_{1/30}$ CV% and LCI$_{1/20}$ CV% or test duration of any LCI end point (table 1).

Table 1: CF and healthy control participant characteristics

<table>
<thead>
<tr>
<th></th>
<th>People with CF</th>
<th>Healthy controls</th>
<th>p Value (CF vs controls)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>30</td>
<td>30</td>
<td>–</td>
</tr>
<tr>
<td>M/F</td>
<td>14/16</td>
<td>16/14</td>
<td>0.61</td>
</tr>
<tr>
<td>Age (years)</td>
<td>20.7 (11.1) (6–51)</td>
<td>20.8 (10.7) (7–44)</td>
<td>0.93</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>79.3 (17.9) (46.0–116.0)</td>
<td>92.9 (11.3) (68.0–116.0)</td>
<td>0.009</td>
</tr>
<tr>
<td>FRC$_{1/40}$ (L)</td>
<td>1.95 (0.76)</td>
<td>2.23 (1.0)</td>
<td>0.22</td>
</tr>
<tr>
<td>LCI$_{1/40}$ (number of turnovers)</td>
<td>9.0 (2.4)</td>
<td>6.4 (0.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LCI$_{1/40}$ CV%</td>
<td>5.2 (2.8)</td>
<td>4.3 (2.0)</td>
<td>0.16</td>
</tr>
<tr>
<td>LCI$_{1/40}$ triplicate test duration (min)</td>
<td>21.8 (9.7) (8.0–57.1)</td>
<td>19.4 (6.5) (10.1–31.1)</td>
<td>0.26</td>
</tr>
<tr>
<td>FRC$_{1/30}$ (L)</td>
<td>1.93 (0.76)</td>
<td>2.24 (1.02)</td>
<td>0.18</td>
</tr>
<tr>
<td>LCI$_{1/30}$ (number of turnovers)</td>
<td>7.7 (1.6)</td>
<td>5.9 (0.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LCI$_{1/30}$ CV%</td>
<td>4.6 (3.2)</td>
<td>4.1 (2.8)</td>
<td>0.53</td>
</tr>
<tr>
<td>LCI$_{1/30}$ triplicate test duration (min)</td>
<td>20.9 (9.1) (7.3–53.2)</td>
<td>18.9 (6.2) (9.9–29.9)</td>
<td>0.34</td>
</tr>
<tr>
<td>FRC$_{1/20}$ (L)</td>
<td>1.90 (0.75)</td>
<td>2.24 (1.0)</td>
<td>0.15</td>
</tr>
<tr>
<td>LCI$_{1/20}$ (number of turnovers)</td>
<td>6.6 (1.2)</td>
<td>5.2 (0.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LCI$_{1/20}$ CV%</td>
<td>5.7 (3.4)</td>
<td>4.6 (2.3)</td>
<td>0.14</td>
</tr>
<tr>
<td>LCI$_{1/20}$ triplicate test duration (min)</td>
<td>20.0 (8.9) (6.7–51.7)</td>
<td>18.3 (5.9) (9.6–28.3)</td>
<td>0.38</td>
</tr>
<tr>
<td>FRC$_{1/10}$ (L)</td>
<td>1.84 (0.73)</td>
<td>2.22 (1.00)</td>
<td>0.09</td>
</tr>
<tr>
<td>LCI$_{1/10}$ (number of turnovers)</td>
<td>4.7 (0.6)</td>
<td>4.0 (0.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LCI$_{1/10}$ CV%</td>
<td>5.4 (3.8)</td>
<td>4.3 (2.8)</td>
<td>0.25</td>
</tr>
<tr>
<td>LCI$_{1/10}$ triplicate test duration (min)</td>
<td>18.6 (8.1) (5.7–46.9)</td>
<td>17.1 (5.5) (8.8–26.6)</td>
<td>0.41</td>
</tr>
</tbody>
</table>

All values summarised as mean (SD)±(range).

CF, cystic fibrosis; CV, coefficient of variation; F, female; FEV$_1$, forced expiratory volume in 1 s; FRC, functional residual capacity; LCI, Lung Clearance Index; M, male.

There was no difference between the CF and control groups in any of the FRC values (FRC$_{1/40}$, FRC$_{1/30}$, FRC$_{1/20}$ or FRC$_{1/10}$). Within the CF group, as expected, FRC was incrementally lower with each earlier end point. Although FRC$_{1/40}$ and FRC$_{1/30}$ were not significantly different (1.95 vs 1.93, p=0.07), FRC$_{1/20}$ (1.95 vs 1.90, p=0.002) and FRC$_{1/40}$ and FRC$_{1/10}$ (1.95 vs 1.84) were significantly different. However, there was no difference between the CF and control groups in any of the FRC values (FRC$_{1/40}$, FRC$_{1/30}$, FRC$_{1/20}$ or FRC$_{1/10}$). Within the CF group, as expected, FRC was incrementally lower with each earlier end point. Although FRC$_{1/40}$ and FRC$_{1/30}$ were not significantly different (1.95 vs 1.93, p=0.07), FRC$_{1/20}$ (1.95 vs 1.90, p=0.002) and FRC$_{1/40}$ and FRC$_{1/10}$ (1.95 vs 1.84) were significantly different.
presence of a normal FEV₁% predicted (figure 3A). Similarly, using LCI₁/30 or LCI₁/20, 7/30 (23%) people with CF had an abnormal LCI in the presence of a normal FEV₁% predicted (figure 3B–C). LCI₁/10 was less sensitive, detecting 5/30 (17%) with an abnormal LCI in the presence of a normal FEV₁% predicted (figure 3D).

ROC curve analysis (figure 4) showed that while all LCI values and FEV₁% predicted had statistically significant levels of sensitivity and specificity in determining people with CF vs control participants, LCI₁/40, LCI₁/30 and LCI₁/20 had comparable and higher sensitivity and specificity compared with LCI₁/10 and FEV₁% predicted (table 2).

**Test duration**

Test duration of LCI₁/30, LCI₁/20 and LCI₁/10 was significantly shorter compared with washout duration of LCI₁/40 in people with CF (p<0.0001) and in healthy controls (p<0.0001; table 1). In people with CF, the mean (95% CI) time saving per triplicate MBW test was 1 (0.8 to 1.3) minutes or 5% with LCI₁/30, 1.9 (1.4 to 2.3) minutes or 9% with LCI₁/20 and 3.3 (2.6 to 4.2) minutes or 15% with LCI₁/10.

**DISCUSSION**

This study is the first to show that SF₆ MBW tests can be reliably shortened. Results show that in children and adults with CF, LCI shortened to 1/30th or 1/20th (LCI₁/30 or LCI₁/20) of the initial concentration have comparable intravisit repeatability and sensitivity to ‘standard’ LCI at 1/40th of the starting concentration (LCI₁/40) providing additional information to FEV₁% predicted and offering a time saving. Although repeatable, LCI shortened to 1/10th of the starting concentration (LCI₁/10) was less sensitive to lung disease, compared with the other LCI end points. It was, however, still more sensitive than FEV₁% predicted.
The ‘standard’ end point of 1/40th is based on historic studies using nitrogen washout (2.5%) and has not been systematically validated for MBW tests using SF6.\(^8\)\(^9\) This study aimed to assess the performance of earlier arbitrary end points compared with the ‘standard’ end point in the SF6 washout, in an attempt to improve the clinical utility of the MBW test by reducing test duration. Like LCI\(_{1/40}\), LCI\(_{1/30}\) and LCI\(_{1/20}\) target the flatter tail of the washout curve, making it unsurprising that similar information can be obtained (see online supplementary file 2). In contrast, when using LCI\(_{1/10}\), the end point occurs before the washout curve flattens. This supports the theory that most information is contained in the tail of the washout curve.\(^16\) Therefore a cut-off before this point may provide less information about lung disease severity, as highlighted by the lower sensitivity of LCI\(_{1/10}\) in this study. Yammine \textit{et al}\(^10\) assessed the repeatability and sensitivity of shortened N\(_2\) MBW to measure LCI, at a number of earlier end points including 1/20th of the starting concentration and as early as 1/5th of the

**Figure 3**  Forced expiratory volume in 1 s (FEV1)% predicted versus (A) LCI\(_{1/40}\); (B) LCI\(_{1/30}\); (C) LCI\(_{1/20}\) (D) LCI\(_{1/10}\) (dotted horizontal lines represent the limits of normal for FEV1% predicted (80% predicted) and LCI (LCI\(_{1/40}\):7.3; LCI\(_{1/30}\):6.7; LCI\(_{1/20}\):5.9; LCI\(_{1/10}\):4.6)).

**Figure 4**  Receiver operating characteristic ROC curve of Lung Clearance Index (LCI)\(_{1/40}\), LCI\(_{1/30}\), LCI\(_{1/20}\), LCI\(_{1/10}\) and inverse forced expiratory volume in 1 s % predicted: sensitivity and specificity to the presence of cystic fibrosis CF.
starting concentration, in 68 children with CF (n=44 with mild disease). In agreement with results from our study, they reported good performance of shortened LCI at 1/20th of the starting concentration compared with ‘standard’ LCI. Furthermore, as with the results from our study, Yammine et al. found that while the earlier LCI end points had good intravisit repeatability, they were less sensitive and specific to the presence of CF. The authors concluded that shortened N₂ MBW to 1/20th of the starting concentration could offer a more feasible measure for use in clinical practice. In this study we extended these observations to investigate and confirm the utility of shortened ventilation indices in older patients with more advanced disease. Theoretically, in cases of severe flow asynchrony between the best and the least ventilated lung units, the end-tidal concentrations in subsequent breathing cycles can enhance the contribution of the least ventilated units toward the end of the washout where LCI is measured. This may lead to increased variation in results taken at an earlier end point, such as 1/20th of the starting concentration. In contrast, LCI from an earlier end point may be more precise, as an end point where the washout curve slope is greater may avoid random breath-by-breath variability that could be observed at a later end point. In this study, LCI₃₀ and LCI₂₀ had marginally better sensitivity to the presence of CF (23% vs 20%), compared with LCI₄₀ even though there was no significant difference in variability (LCI CV%) between ‘standard’ LCI (LCI₄₀) and LCI at an earlier end point (LCI₃₀, LCI₂₀, LCI₁₀). LCI₃₀ and LCI₂₀ also had good diagnostic performance and superior sensitivity compared with FEV₁% predicted. Importantly, these findings indicate that no further additional information was obtained using LCI₄₀ compared with the shortened versions, LCI₃₀ and LCI₂₀.

Test duration for LCI₃₀, LCI₂₀ and LCI₁₀ was significantly shorter than LCI₄₀ in people with CF, with an average 5%, 9% and 15% time saving, respectively. As LCI₂₀ offers a greater time saving than LCI₃₀, while maintaining reliability and sensitivity, it provides the most attractive measure and may enhance the feasibility of MBW in the research and clinical setting. The proportion of time saved in this study is smaller than that reported in the study by Yammine et al. as MBW tests using an exogenous gas such as SF₆ require a washin and a washout phase. However, as these results are from a retrospective analysis, the time saving measurement does not take into account the total time saving per testing session. Finishing a test earlier would allow for the second and third test of the triplicate to start sooner, resulting in a larger time saving. Although the washin time is unchanged, any shortening of LCI test duration could be especially useful in younger children where long assessment periods are not feasible, and in patients with advanced disease, where the washin and/or washout periods can be prolonged. The use of MBW equipment using SF₆ has been successfully used in multicentre studies and remains popular as it has advantages in terms of tracer gas estimation (measured directly rather than by subtraction as with N₂ MBW) avoiding the potential confounding effects of 100% O₂ on breathing pattern. This study is the first to show that MBW using SF₆ can be reliably shortened.

Considering potential limitations of shortened MBW tests, one study highlights that advanced analysis of washout curves to determine the relative contribution of convective and acinar airways to ventilation heterogeneity (phase III analysis) usually requires six lung-volume turnovers. However, recent work suggests that the same information may be obtainable in three lung-volume turnovers in which case use of LCI₂₀ would still enable full phase III analysis. Regardless, phase III indices may have limited utility in CF, as demonstrated by Horsley et al. The retrospective nature of this study is a limitation. However, the study did endeavour to avoid selection bias by use of anonymised patient data sets as consecutively listed in a database and represents the first exploratory study to report on the clinimetric properties of an earlier end point in SF₆ MBW. More data from across the disease severity range in CF are required to define normal ranges of shortened LCI.

### CONCLUSIONS

LCI₂₀ is a repeatable and sensitive test with equal diagnostic performance to LCI₄₀ that is shorter, potentially offering a more feasible research and clinical measure.

#### Acknowledgements

The authors would like to thank the patients and families who participated in this study.

#### Contributors

KO’N recruited patients, collected clinical data, conducted MBW tests and performed lung function assessment; KO’N, DH, JSE and NB analysed data; IB provided statistical analysis support; KO’N, DH, JMB, NB and JSE wrote the paper.

#### Funding

Work funded by HSC Research and Development, Public Health Agency, Northern Ireland and the Medical Research Council through a US-Ireland Partnership Grant.

#### Competing interests

None.

#### Patient consent

Obtained.

#### Ethics approval

This study was approved by the Office for Research Ethics Committees Northern Ireland (ORECNI) (REC reference number: 10/NIR01/41)

---

**Table 2** AUC₉₅ and 95% CI for LCI₄₀, LCI₃₀, LCI₂₀, LCI₁₀ and inverse FEV₁% predicted (1.0 indicating best performance, 0.5 indicating poor performance).

<table>
<thead>
<tr>
<th>AUC₉₅</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCI₄₀</td>
<td>0.89</td>
<td>0.80 to 0.97</td>
</tr>
<tr>
<td>LCI₃₀</td>
<td>0.87</td>
<td>0.77 to 0.96</td>
</tr>
<tr>
<td>LCI₂₀</td>
<td>0.87</td>
<td>0.78 to 0.96</td>
</tr>
<tr>
<td>LCI₁₀</td>
<td>0.83</td>
<td>0.72 to 0.94</td>
</tr>
<tr>
<td>FEV₁%</td>
<td>0.73</td>
<td>0.60 to 0.86</td>
</tr>
</tbody>
</table>

AUC, area under the curve; FEV₁, forced expiratory volume in 1 s; LCI, Lung Clearance Index; ROC, receiver operating characteristic.
and co-sponsored by BHSCT and QUB (research office reference number: 10067SE-OPMS).

Provenance and peer review  Not commissioned; externally peer reviewed.

Open Access  This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES
Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis

David Hannon, Judy M Bradley, Ian Bradbury, et al.

*BMJ Open Resp Res* 2014 1:
doi: 10.1136/bmjresp-2014-000031

Updated information and services can be found at:
http://bmjopenrespres.bmj.com/content/1/1/e000031.full.html

These include:

**References**
This article cites 19 articles, 10 of which can be accessed free at:
http://bmjopenrespres.bmj.com/content/1/1/e000031.full.html#ref-list-1

**Open Access**
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/